Investor relations
Thank you for reaching out to the Investor Relations team at Aurora. We appreciate you sharing your frustrations with us. There are several factors in the market dictating the prices of a stock and it is not entirely controlled by a Company. Auroras management has worked incredibly hard to build a business that is vertically integrated and horizontally diversified across every key segment of the cannabis value chain with 17 acquisitions and 13 strategic investments. From facility engineering and design to cannabis breeding, genetics research, production, high value-add product development, home cultivation, and wholesale and retail distribution. Our management team has implemented an aggressive strategy to build a preeminent global leader in the cannabis industry with presence across 24 countries across 5 continents, and we are right on track with this strategy. Nelson Peltz continues to be a strategic advisor with Aurora to strategically explore potential partnerships that would be optimal strategic fit for successful entry into each of Auroras contemplated market segments. I encourage you to look at our Q3 2019 Financials, where the Company reported a net revenues of $58.6 million, a 443% increase in revenue compared to the same period in 2018. Consequently, management believes the combination of substantial revenue growth and disciplined cost management positions the Company well to achieve sustained positive EBIDTA beginning in Fiscal Q4 2019 (Calendar Q2 2019). With Aurora Sky and MedReleaf Bradford (now, Aurora River) operating in full capacity, the cash cost to producer per gram declined 26% to $1.42 per gram. With the second phase of legalization of consumer cannabis in Canada, we are ramping up production. In Q3 2019, the production volume increased 99% to 15,590 kilograms. Aurora continues solid revenue growth averaging 20% across all key markets, driven by successful scale up of the Companys production and continued strong performance across the Canadian consumer, and the Canadian and International medical cannabis markets. In this quarter, we announced an exclusive, multi-year, multi-million dollar, global partnership with UFC, the worlds premier mixed martial arts organization that is expected to significantly advance our clinical research between 100% hemp derived CBD products and athlete wellness and recovery. This will help accelerate CBD product development and education and help Aurora fuel the global CBD wellness markets.